Skip to content

Effect of ayurvedic lepa preparations in the management of melasma(vyanga).

Cosmetology In Ä?yurveda - A Literary Review And Comparative Therapeutic Trial Of MukhakÄ?ntivardhaka lepa And Arjuna tvak lepa In The Management Of vyaá¹?ga with special reference to Melasma

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/04/032828
Enrollment
100
Registered
2021-04-15
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L811- Chloasma

Interventions

Intervention1: Mukhakantivardhak lepa: Group A: - In this group patients will be treated with powder of MukhakÄ?ntivardhaka lepa as (face pack) which will be applied on face with adequate GulÄ?ba jal

Sponsors

National institute of ayurveda
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Subjects of either sex with age group above 18 years will be selected. 2.Subjects with Fitzpatrick skin types III, IV and V presenting with the classical signs and symptoms of Vyaá¹?ga(melasma) will be selected. 3.Subjects willing to participate in the study and willing to give written informed consent will be selected by explaining the interventions in detail. 4.Female subjects of childbearing potential using a reliable from of contraception during the course of the study excluding oral contraceptive pills at the time of the study or in the past 6 months (intrauterine device or condoms) or female of nonchildbearing potential (hysterectomy, bilateral ovariectomy or tubal section/ligation). 5.Female subjects of childbearing potential with a negative urine pregnancy test before inclusion in the study.

Exclusion criteria

Exclusion criteria: 1.Hyperpigmentation caused since birth like nevus of ota. 2.Hyperpigmentation caused by tumor like malignant melanoma. 3.Vya�ga along with other kuṣṭha roga to be excluded. 4.Pregnant women, nursing mothers. 5.Subjects suffering from other pigmentation disorders. 6.Subject having used any cosmetic depigmenting agent within 2 weeks prior to inclusion. 7.Subjects who have used a topical or inhaled corticosteroid or systemic steroids within 1 month prior to inclusion in the study. 8.Subjects having used topical tretinoin within 3 months or topical hydroquinone within 6 months prior to inclusion. 9.Subjects with history of endocrinopathies.

Design outcomes

Primary

MeasureTime frame
Reduction in classical signs and symptoms of vyaá¹?ga.Timepoint: 45 days

Secondary

MeasureTime frame
Better quality of life.Timepoint: 45 days

Countries

India

Contacts

Public ContactShivaganga

National institute of ayurveda jaipur

drreetusharma@gmail.com7892905849

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026